EASL Studio Podcast: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy episode artwork

EPISODE · Feb 29, 2024 · 35 MIN

EASL Studio Podcast: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

from EASL Podcasts

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.FacultyAleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodesEASL Studio from EASL Congress 2023: Clinical trials in rare diseases – opportunities and challengesEASL Studio from ILC 2022: Rare Liver Diseases – A growing landscape of opportunities and challengesThis episode is scheduled in honour of the Rare Disease Day (29 February).All EASL Studio Podcasts are available on EASL Campus.

Episode metadata supplied by the publisher feed · Published Feb 29, 2024

Embed this episode

NOW PLAYING

EASL Studio Podcast: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

0:00 35:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EASL Podcasts?

This episode is 35 minutes long.

When was this EASL Podcasts episode published?

This episode was published on February 29, 2024.

Can I download this EASL Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!